Case Report
Immune Thrombocytopenia and JAK2V617F Positive Essential Thrombocythemia: Literature Review and Case Report
Table 1
MPN Ph(−) and ITP case reports.
| Case number | 1 | 2 | 3 |
| Authors | Huang CE et al. [9] | Farhat et al. [10] | Sobas et al. [this report] |
| Sex | Female | Female | Female |
| ITP diagnosis | January 2009 (14 y.o.) | October 2001 | July 1992 (45 y.o.) |
| ITP treatment | (1) DXM × 5 (2) Splenectomy (Aug. 2012) | (1) DXM × 4 (2) Igs (no data about doses) | (1) PD 1 mg/kg × 3 (1st and 2nd relapse) (2) After ET dgn: (i) 3rd ITP relapse: Igs 0,4 mg/kg × 5 days + AZT (ii) 4th ITP relapse: PD + AZT |
| ET diagnosis | August 2012: highly probable | March 2001 | January 2013 |
| JAK2 mutation | Positive: 11% allele burden | Positive | Positive |
| BM biopsy | Not done (patient refused) | Compatible with ET (2001) | Compatible with ET (2013) |
| MPN – ITP latency | Not known | ITP diagnosed 8 months after ET diagnosis (in 1994 patient was diagnosed with TTP) | ET diagnosed after 21 years of follow-up |
| Splenomegaly | No | No | No |
| ET treatment | No data | (1) Aspirin and ANA for 2 months, no response (2) HU | HU |
|
|
Bone marrow (BM) biopsy, dexamethasone (DXM) 40 mg/day × 4 days, immunoglobulins (Igs), TTP (thrombotic thrombocytopenic purpura), ANA (anagrelide), HU (hydroxyurea), prednisone (PD), and azathioprine (AZT).
|